Abstract Details

Title Medical Cannabis in the Treatment of Neuropathy

Topic General Neurology

Presentation(s) General Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 098

Objective To evaluate the efficacy and adverse effects of medical cannabis (MC) in the treatment of neuropathy

Background According to the National Institutes of Health, more than 20 million Americans suffer from neuropathy. With MC now legal in 33 states, MC presents as an anti-inflammatory and neuroprotective agent that may help in treating neuropathy and associated symptoms.

Design/Methods This retrospective chart analysis was conducted on patients with neuropathy as diagnosed by a board-certified neurologist in a comprehensive, neurologic outpatient setting in New York State. All patients were subsequently certified to use MC as part of New York State’s Medical Marijuana Program.

Results 503 (247=male, 255= female) patients age 22-99 years with neuropathy were included for this analysis. 85.1% of the study population reported benefit from using MC, with 82.5% percent of patient population (n=415) reporting a decrease in neuropathic pain/symptoms. 77.3% of the study population was able to achieve these results using only one MC product. The majority of patients used MC in tincture form (77.1%), with ratios of 20:1 (THC:CBD) and 1:1 (THC:CBD) representing 79.5% of MC products. Average daily exposures to THC and CBD were 27.2mg and 19.4mg respectively. We found that 28.0% (n=141) of the population reported side effects which were generally mild in nature. The most commonly reported side effects were fatigue (n=29), increased appetite (n=24), drowsiness (n=20), and dizziness (n=19). Less than 1.0% (n=2) chose to stop MC treatment due to side effects. No severe AE were reported.

Conclusions MC as a part of a comprehensive neuropathic pain care is well tolerated and may play a role in advancing conventional care plans. The most common MC ratios used to achieve such results were 20:1 (THC:CBD) and 1:1 (THC:CBD). Further investigations, including randomized placebo-controlled trials are needed to confirm these promising results in the treatment of neuropathy.

Authors/Disclosures
Paul B. Hart PRESENTER	Mr. Hart has nothing to disclose.
Laszlo Mechtler, MD, FEAN, FASN, FAHS, FAAN (Dent Neurologic Institute)	Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharma. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Genomate Health. The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc. The institution of Dr. Mechtler has received research support from Alpheus medical. The institution of Dr. Mechtler has received research support from Shiratronics. The institution of Dr. Mechtler has received research support from Abbvie Inc. The institution of Dr. Mechtler has received research support from Amgen. The institution of Dr. Mechtler has received research support from Eli Lilly Company. The institution of Dr. Mechtler has received research support from H. Lundbeck HS. The institution of Dr. Mechtler has received research support from Pfizer. Dr. Mechtler has received personal compensation in the range of $100,000-$499,999 for serving as a Ownership interest with Neurology Practce Consortium GPO. Dr. Mechtler has a non-compensated relationship as a Board member with International Headache Society that is relevant to AAN interests or activities.
Laszlo Mechtler, MD, FEAN, FASN, FAHS, FAAN (Dent Neurologic Institute)	Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharma. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Genomate Health. The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc. The institution of Dr. Mechtler has received research support from Alpheus medical. The institution of Dr. Mechtler has received research support from Shiratronics. The institution of Dr. Mechtler has received research support from Abbvie Inc. The institution of Dr. Mechtler has received research support from Amgen. The institution of Dr. Mechtler has received research support from Eli Lilly Company. The institution of Dr. Mechtler has received research support from H. Lundbeck HS. The institution of Dr. Mechtler has received research support from Pfizer. Dr. Mechtler has received personal compensation in the range of $100,000-$499,999 for serving as a Ownership interest with Neurology Practce Consortium GPO. Dr. Mechtler has a non-compensated relationship as a Board member with International Headache Society that is relevant to AAN interests or activities.
Laszlo Mechtler, MD, FEAN, FASN, FAHS, FAAN (Dent Neurologic Institute)	Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharma. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Genomate Health. The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc. The institution of Dr. Mechtler has received research support from Alpheus medical. The institution of Dr. Mechtler has received research support from Shiratronics. The institution of Dr. Mechtler has received research support from Abbvie Inc. The institution of Dr. Mechtler has received research support from Amgen. The institution of Dr. Mechtler has received research support from Eli Lilly Company. The institution of Dr. Mechtler has received research support from H. Lundbeck HS. The institution of Dr. Mechtler has received research support from Pfizer. Dr. Mechtler has received personal compensation in the range of $100,000-$499,999 for serving as a Ownership interest with Neurology Practce Consortium GPO. Dr. Mechtler has a non-compensated relationship as a Board member with International Headache Society that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��